Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 03 2024 - 8:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
03
October 2024 - “Completion of off-market purchase and Total
Voting”
|
99.1
Haleon plc: Completion of off-market
purchase and Total Voting Rights and Capital
3 October 2024: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces
that it has completed the off-market purchase of 60,526,315
ordinary shares of £0.01 each, repurchased from Pfizer Inc.
("Pfizer") for an aggregate purchase price of £230
million.
The off-market purchase includes (i) 30,161,278 ordinary shares
which Haleon has
cancelled and (ii) 30,365,037 ordinary shares which will be held as
treasury shares.
As at 3 October 2024, the total number of ordinary shares issued
by Haleon is
9,083,725,919, of which 30,365,037 are held as treasury shares.
Therefore, the number of ordinary shares with voting rights is
9,053,360,882 and this figure may be used by shareholders (and
others with notification obligations) as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Sonya
Ghobrial
|
+44
7392 784784
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Gemma
Thomas
|
+44 7985 175048
|
|
Emma
White
|
+44
7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information please visit www.haleon.com
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date: October
03, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Oct 2024 to Nov 2024
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Nov 2023 to Nov 2024
